影像组学预测肝细胞癌免疫组化标志物的研究进展  

Research progress on radiomics in predicting immunohistochemical biomarkers of hepatocellular carcinoma

作　　者：尹韵清 张伟[2] 张彦舫 沈新颖(审校) YIN Yunqing;ZHANG Wei;ZHANG Yanfang;SHEN Xinying(The Second Clinical Medical College,Jinan University,Shenzhen 518020,China;Department of Interventional Radiology,Shenzhen People’s Hospital)

机构地区：[1]暨南大学第二临床医学院,深圳518020 [2]深圳市人民医院介入放射科

出　　处：《国际医学放射学杂志》2024年第6期719-724,共6页International Journal of Medical Radiology

基　　金：深圳市科技计划项目(JCYJ20210324112611031)。

摘　　要：免疫组化标志物对肝细胞癌(HCC)病人的预后分析和个性化治疗有重要的指导意义。目前免疫组化主要依靠手术病理或组织活检等有创方法,而影像组学具有广泛表征空间异质性的潜力,可以于术前无创预测与HCC相关的免疫组化标志物。就影像组学预测HCC Ki-67等免疫组化标志物的研究进展予以综述,并就其在该研究领域的应用前景进行展望。Immunohistochemical markers play a significant role in the prognosis analysis and personalized treatment of patients with hepatocellular carcinoma(HCC).Currently,immunohistochemistry mainly relies on invasive methods such as surgical pathology or tissue biopsy.However,radiomics has great potential for non-invasively predicting HCC-related immunohistochemical markers before surgery by broadly characterizing spatial heterogeneity.This review summarizes the research progress on radiomics for predicting immunohistochemical markers such as Ki-67 in HCC and discusses the prospects for its application in this research field.

关 键 词：影像组学 肝细胞癌 免疫组织化学标志物 磁共振成像 超声 体层摄影术 X线计算机 

分 类 号：R814.42[医药卫生—影像医学与核医学] R816.5[医药卫生—放射医学] R446.6[医药卫生—临床医学]